A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ETON SEC filings page.
Eton Pharmaceutcials, Inc. (ETON) reported $80.0M in revenue for fiscal year 2025, up 104.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Eton’s expansion now generates operating cash, but lower gross margins and a liability-heavy balance sheet still leave accounting losses.
Eton’s cash conversion improved before profitability: FY2025 operating cash flow reached$10.5M while the company still posted a net loss of$4.6M , showing that cash generation and accounting earnings were pulling in different directions. Meanwhile, gross margin fell6.6 percentage points as sales expanded sharply, so the improvement was not driven by a richer margin structure.
The balance-sheet posture is increasingly liability-funded: liabilities were
FY2025 free cash flow was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Eton Pharmaceutcials, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Eton Pharmaceutcials, Inc. held $25.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $10.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Eton Pharmaceutcials, Inc. scores 87/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Eton Pharmaceutcials, Inc. scores 73/100 on it among other emerging companies.
Eton Pharmaceutcials, Inc. spent $7.8M on research and development in fiscal year 2025, which was 9.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Eton Pharmaceutcials, Inc. scores 37/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Eton Pharmaceutcials, Inc. scores 80/100 on it among other emerging companies.
Not available for Eton Pharmaceutcials, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Eton Pharmaceutcials, Inc.'s cash, cash equivalents and investments came to $25.9M at the end of fiscal year 2025, against $66.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Eton Pharmaceutcials, Inc. scores 39/100 among other emerging companies.
Eton Pharmaceutcials, Inc. scores 15.38, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $1.8B against total liabilities of $66.0M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Eton Pharmaceutcials, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Eton Pharmaceutcials, Inc. reported a net loss of $4.6M while generating $10.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Eton Pharmaceutcials, Inc. reported an operating loss of $844K against $4.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Eton Pharmaceutcials, Inc. generated $57.9M in revenue in Q3 2026. This represents an increase of 157.9% from the same quarter a year earlier. Against the prior quarter it is up 54.1%.
Eton Pharmaceutcials, Inc.'s EBITDA was $24.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 72.5%.
Eton Pharmaceutcials, Inc. reported $35.2M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 204.4%.
Eton Pharmaceutcials, Inc. earned $1.06 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 202.9%.
Cash & Balance Sheet
Eton Pharmaceutcials, Inc. generated $35.2M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 200.0% from the same quarter a year earlier.
Eton Pharmaceutcials, Inc. held $55.6M in cash against $11.2M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Eton Pharmaceutcials, Inc.'s gross margin was 76.5% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 41.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.9 percentage points.
Eton Pharmaceutcials, Inc.'s operating margin was 39.7% in Q3 2026, reflecting core business profitability. This is up 45.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.7 percentage points.
Eton Pharmaceutcials, Inc.'s net profit margin was 60.9% in Q3 2026, showing the share of revenue converted to profit. This is up 69.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 30.1 percentage points.
Eton Pharmaceutcials, Inc.'s quarterly ROE was 40.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 48.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 15.7 percentage points.
Capital Allocation
Eton Pharmaceutcials, Inc. invested $5.3M in research and development in Q3 2026. This represents an increase of 374.0% from the same quarter a year earlier. Against the prior quarter it is up 430.8%.
Eton Pharmaceutcials, Inc. invested $13K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 95.4% from the same quarter a year earlier.
Not reported for Q3 2026.
ETON Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57.9M+157.9% | $37.6M+98.6% | $24.3M+40.4% | $21.3M+82.7% | $22.5M+117.5% | $18.9M+108.6% | $17.3M+116.9% | $11.6M+59.3% |
| Cost of Revenue | $13.6M-6.7% | $12.2M+73.8% | $9.5M+28.4% | $8.2M+58.2% | $14.6M+263.1% | $7.0M+103.1% | $7.4M+150.8% | $5.2M+40.4% |
| Gross Profit | $44.3M+464.0% | $25.4M+113.1% | $14.7M+49.4% | $13.1M+102.3% | $7.9M+24.6% | $11.9M+111.9% | $9.9M+96.9% | $6.5M+78.4% |
| R&D Expenses | $5.3M+374.0% | $993K-73.2% | $1.9M+61.5% | $1.8M | $1.1M+120.2% | $3.7M+25.0% | $1.2M+78.3% | N/A |
| SG&A Expenses | $16.0M+97.6% | $11.6M+20.0% | $10.4M+13.9% | $8.9M+31.8% | $8.1M+53.3% | $9.7M+73.3% | $9.2M+77.9% | $6.7M+46.8% |
| Operating Income | $23.0Mn/m | $12.8Mn/m | $2.4Mn/m | $2.5M+291.7% | -$1.4M-367.8% | -$1.5Mn/m | -$470Kn/m | $629Kn/m |
| EBITDA | $24.5Mn/m | $14.2Mn/m | $3.5M+552.9% | $3.5M+253.8% | -$354K-144.9% | -$470Kn/m | $543Kn/m | $984Kn/m |
| Interest Expense | $959K-20.9% | $1.1M+3.1% | $1.1M-2.3% | $1.4M+49.3% | $1.2M+474.4% | $1.0M+1907.7% | $1.2M+40.1% | $912Kn/m |
| Income Tax | -$12.9Mn/m | $140K+112.1% | $20K-73.0% | -$69K-179.3% | -$28Kn/m | $66K+22.2% | $74Kn/m | $87K-64.8% |
| Net Income | $35.2Mn/m | $11.6Mn/m | $1.6Mn/m | $1.5Mn/m | -$1.9M-407.3% | -$2.6Mn/m | -$1.6Mn/m | -$598Kn/m |
| EPS (Basic) | $1.23n/m | $0.42n/m | $0.06n/m | $0.06n/m | -$0.07-450.0% | -$0.10n/m | -$0.06n/m | -$0.03n/m |
| EPS (Diluted) | $1.06n/m | $0.35n/m | $0.05n/m | N/A | -$0.07-450.0% | -$0.10n/m | -$0.06n/m | N/A |
| Diluted Shares (Avg) | 33M+23.7% | 33M+21.9% | 32M+17.3% | N/A | 27M+1.3% | 27M+4.3% | 27M+4.4% | N/A |
ETON Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $157.3M+50.5% | $115.8M+13.9% | $97.7M+16.3% | $92.1M+21.0% | $104.5M+191.6% | $101.7M+219.5% | $84.0M+172.9% | $76.1M+139.8% |
| Current Assets | $96.8M+34.4% | $68.6M+0.2% | $53.2M+6.6% | $60.6M+47.7% | $72.0M+142.0% | $68.4M+169.1% | $50.0M+105.9% | $41.0M+52.8% |
| Cash & Equivalents | $55.6M+49.9% | $26.8M+5.8% | $19.7M+12.9% | $25.9M+73.7% | $37.1M+83.2% | $25.4M+43.4% | $17.4M+4.6% | $14.9M-30.2% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $11.1M-34.3% | $10.1M-57.4% | $14.5M+6.2% | $15.4M+1.2% | $16.9M+769.7% | $23.8M+1050.4% | $13.6M+487.6% | $15.2M+1572.0% |
| Accounts Receivable | $26.4M+102.0% | $24.9M+72.2% | $13.4M-18.2% | $11.8M+119.3% | $13.1M+134.0% | $14.5M+196.6% | $16.4M+286.8% | $5.4M+57.2% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $70.3M-13.6% | $69.2M-10.9% | $67.1M+12.6% | $66.0M+27.6% | $81.4M+309.8% | $77.7M+323.3% | $59.6M+289.4% | $51.7M+217.9% |
| Current Liabilities | $54.1M+22.4% | $45.1M+16.9% | $44.2M+74.3% | $38.5M+93.0% | $44.2M+123.9% | $38.6M+111.9% | $25.4M+65.7% | $19.9M+22.8% |
| Non-Current Liabilities | $16.3M-56.3% | $24.1M-38.4% | $22.9M-33.1% | $27.5M-13.5% | $37.2M+29424.6% | $39.1M+26878.6% | $34.2Mn/m | $31.7M+144209.1% |
| Long-Term Debt | $11.2M-59.3% | $19.1M-30.4% | $18.9M-36.9% | $21.8M-27.0% | $27.6M | $27.4M | $30.0M | $29.8Mn/m |
| Total Equity | $86.9M+275.9% | $46.6M+94.4% | $30.6M+25.2% | $26.2M+7.1% | $23.1M+44.7% | $24.0M+78.0% | $24.4M+57.8% | $24.4M+57.8% |
| Retained Earnings | -$64.1Mn/m | -$99.4Mn/m | -$110.9Mn/m | -$112.5Mn/m | -$114.0Mn/m | -$112.0Mn/m | -$109.5Mn/m | -$107.9Mn/m |
Not reported in any period shown, so not listed: Goodwill.
ETON Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $35.2M+193.0% | $7.3M-8.8% | $7.4M+254.3% | -$11.6Mn/m | $12.0M+307.4% | $8.0M+534.2% | $2.1Mn/m | -$765K-297.7% |
| Depreciation & Amortization | $1.4M+43.1% | $1.4M+37.9% | $1.1M+11.6% | $1.0M+186.5% | $1.0M+261.6% | $1.0M+260.2% | $1.0M+332.9% | $355K+9.2% |
| Stock-Based Compensation | $3.3M+203.0% | N/A | $1.5M+26.5% | N/A | $1.1M-54.2% | N/A | $1.2M+46.2% | N/A |
| Capital Expenditures | $13K-95.4% | N/A | $75Kn/m | $49K+308.3% | $284Kn/m | $0n/m | $0-100.0% | $12Kn/m |
| Free Cash Flow | $35.2M+200.0% | N/A | $7.3M+250.7% | -$11.6Mn/m | $11.7M+297.8% | $8.0M+534.2% | $2.1Mn/m | -$777K-300.8% |
| Investing Cash Flow | -$3.2Mn/m | $5Kn/m | -$15.1Mn/m | -$49Kn/m | -$284Kn/m | $0n/m | $0n/m | -$38.1Mn/m |
| Financing Cash Flow | -$3.2Mn/m | -$76Kn/m | $1.4M+252.5% | $421K-98.7% | $0n/m | $0n/m | $394Kn/m | $33.6Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ETON Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.5%+41.5pp | 67.6%+4.6pp | 60.7%+3.7pp | 61.6%+6.0pp | 35.0%-26.1pp | 63.0%+1.0pp | 57.1%-5.8pp | 55.6%+6.0pp |
| Operating Margin | 39.7%+45.8pp | 34.0%+41.8pp | 10.0%+12.7pp | 11.6%+6.2pp | -6.1%-11.0pp | -7.8%+24.6pp | -2.7%+7.3pp | 5.4%+32.6pp |
| Net Margin | 60.9%+69.4pp | 30.8%+44.5pp | 6.4%+15.5pp | 7.0%+12.1pp | -8.6%-14.6pp | -13.7%+19.9pp | -9.1%+1.1pp | -5.1%+25.7pp |
| Return on Equity | 40.6%+48.9pp | 24.9%+35.6pp | 5.1%+11.5pp | 5.7%+8.1pp | -8.3%-12.3pp | -10.8%+11.8pp | -6.4%-1.2pp | -2.5%+12.1pp |
| Return on Assets | 22.4%+24.3pp | 10.0%+12.5pp | 1.6%+3.5pp | 1.6%+2.4pp | -1.8%-3.6pp | -2.5%+7.0pp | -1.9%+0.8pp | -0.8%+6.3pp |
| Current Ratio | 1.79+0.2x | 1.52-0.3x | 1.21-0.8x | 1.57-0.5x | 1.63+0.1x | 1.77+0.4x | 1.97+0.4x | 2.06+0.4x |
| Debt-to-Equity | 0.13-1.1x | 0.41-0.7x | 0.62-0.6x | 0.83-0.4x | 1.19 | 1.14 | 1.23 | 1.22+1.2x |
| Liabilities-to-Equity | 0.81-2.7x | 1.49-1.8x | 2.19-0.2x | 2.52+0.4x | 3.52+2.3x | 3.24+1.9x | 2.44+1.4x | 2.12+1.1x |
| Asset Turnover | 0.37+0.2x | 0.32+0.1x | 0.250.0x | 0.23+0.1x | 0.21-0.1x | 0.19-0.1x | 0.21-0.1x | 0.15-0.1x |
| FCF Margin | 60.8%+8.5pp | N/A | 30.2%+18.1pp | -54.5%-47.8pp | 52.3%+23.7pp | 42.0%+28.2pp | 12.1%+43.3pp | -6.7%-12.0pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Eton Pharmaceutcials, Inc. ETON | FY2025 | $80.0M | -$4.6M | -5.8% | $1.8B | 63/100 |
| BioCryst Pharmaceuticals Inc BCRX | FY2025 | $874.8M | $263.9M | 30.2% | $1.9B | 72/100 |
| ANI Pharmaceuticals, Inc. ANIP | FY2025 | $883.4M | $78.3M | 8.9% | $1.6B | 67/100 |
| Alvotech ALVO | FY2025 | $586.3M | $27.9M | 4.8% | $1.5B | 34/100 |
| Pacira BioSciences, Inc. PCRX | FY2025 | $726.4M | $7.0M | 1.0% | $1.5B | 54/100 |
| Phibro Animal Health Corporation PAHC | FY2026 | $1.5B | $99.7M | 6.6% | $1.4B | 62/100 |
Where Eton Pharmaceutcials, Inc. Ranks
Frequently Asked Questions
Eton Pharmaceutcials, Inc. (ETON) reported $80.0M in total revenue for fiscal year 2025. This represents a 104.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Eton Pharmaceutcials, Inc. (ETON) revenue grew by 104.9% year-over-year, from $39.0M to $80.0M in fiscal year 2025.
No, Eton Pharmaceutcials, Inc. (ETON) reported a net loss of $4.6M in fiscal year 2025, with a net profit margin of -5.8%.
Eton Pharmaceutcials, Inc. (ETON) had EBITDA of $3.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Eton Pharmaceutcials, Inc. (ETON) had $25.9M in cash and equivalents against $21.8M in long-term debt.
Eton Pharmaceutcials, Inc. (ETON) had a gross margin of 53.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Eton Pharmaceutcials, Inc. (ETON) had an operating margin of -1.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Eton Pharmaceutcials, Inc. (ETON) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Eton Pharmaceutcials, Inc. (ETON) has a return on equity of -17.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Eton Pharmaceutcials, Inc. (ETON) generated $10.2M in free cash flow during fiscal year 2025. This represents a 980.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Eton Pharmaceutcials, Inc. (ETON) generated $10.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Eton Pharmaceutcials, Inc. (ETON) had $92.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Eton Pharmaceutcials, Inc. (ETON) invested $333K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Eton Pharmaceutcials, Inc. (ETON) invested $7.8M in research and development during fiscal year 2025.
Eton Pharmaceutcials, Inc. (ETON) had a current ratio of 1.57 as of fiscal year 2025, which is generally considered healthy.
Eton Pharmaceutcials, Inc. (ETON) had a debt-to-equity ratio of 0.83 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Eton Pharmaceutcials, Inc. (ETON) had a liabilities-to-equity ratio of 2.52 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Eton Pharmaceutcials, Inc. (ETON) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Eton Pharmaceutcials, Inc. (ETON) trades at 35.2x earnings, its market capitalization divided by $49.9M net income, trailing 12 months to September 30, 2026. The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Eton Pharmaceutcials, Inc. (ETON) trades at 12.4x sales, its market capitalization divided by $141.1M revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Eton Pharmaceutcials, Inc. (ETON) has an Altman Z-Score of 15.38, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Eton Pharmaceutcials, Inc. (ETON) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Eton Pharmaceutcials, Inc. (ETON) reported a net loss of $4.6M while generating $10.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Eton Pharmaceutcials, Inc. (ETON) reported an operating loss of $844K against $4.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Eton Pharmaceutcials, Inc. (ETON) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Eton Pharmaceutcials, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.